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matched samples of employees with osteoarthritis (OA) and non-
FM controls. METHODS: Samples were selected from a U.S.
claims database of privately insured beneﬁciaries. Employees in
the FM sample had ≥2 ﬁbromyalgia diagnoses in 1999–2005
(with ≥1 in 2002–2005) and were continuously enrolled in 2005.
Controls and employees with OA had no FM claims and were
matched to the study sample on age, gender, and region. Costs
are reported for 2005 experience. Nonparametric Wilcoxon tests
were used to determine statistically signiﬁcant differences in
skewed variables including costs. Chi-square tests were used to
test for differences in for categorical variables. RESULTS: Mean
age in the FM sample was 50.1 years and 51.6% were female.
Compared to control and OA samples, employees with FM had
higher rates of depression, anxiety, chronic fatigue syndrome,
and many pain diagnoses. The FM sample used more medical
care overall, especially emergency department visits, specialty
physician visits, and prescriptions. Direct (medical and prescrip-
tion drug) costs in the FM sample were signiﬁcantly higher 
than control sample costs ($7286 vs. $3915, p < 0.0001), and
approached OA sample costs ($7286 vs. $8325, p = 0.3758).
Prescription costs comprised a relatively large proportion of total
FM costs; prescription cost levels were comparable to employ-
ees with OA ($1630 vs. $1341, p < 0.3541) and signiﬁcantly
higher than controls ($1630 vs. $755, p < 0.0001). Work loss
costs in the FM sample ($2913) were signiﬁcantly higher than
those of control ($1359, p < 0.0001) and OA ($2537, p <
0.0001) samples. CONCLUSIONS: Fibromyalgia imposes sig-
niﬁcant economic burden. Average total costs among employees
with ﬁbromyalgia were almost twice those of matched controls
and approximated costs of employees with osteoarthritis. Indi-
rect costs were more than double those of controls and even
exceeded costs of osteoarthritis patients with similar demo-
graphic proﬁles.
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OBJECTIVES: Patients with insomnia are likely to have comor-
bidities that could affect treatment options. Hence the objective
of this study was to examine the prevalence of comorbidities and
their impact on the pharmacological treatment of insomnia in
US primary care settings. METHODS: A retrospective data
analysis of the National Ambulatory Medical Care Survey from
1995 to 2004 was performed. Patients aged ≥18 years, who had
a physician visit with a diagnosis of insomnia in US outpatient
settings were included in this study. Ofﬁce visits of patients with
primary or secondary insomnia/sleep complaints and resultant
diagnoses were included in the analysis. Data were stratiﬁed
according to patient characteristics, physician specialty, resulting
diagnosis and medications prescribed. Multivariate logistic
regression models were used to examine impact on prescribing
pharmacotherapy for insomnia. RESULTS: A total of 5487
unweighted patient visits for insomnia were identiﬁed from the
year 1995–2004, representing 107.4 million patients in the
overall U.S. population. Ofﬁcial visits for insomnia were more
common in females (60.4%), with an increasing prevalence in
older patients. Approximately 41% of the patients with insom-
nia had a concomitant diagnosis of a mental comorbidity with
higher prevalence of anxiety (15.6%) followed by episodic mood
disorders (14.9%) and depression (7%). Patients with mental
comorbidities were 35% less likely to receive pharmacological
treatment for insomnia than those without mental comorbidities
(OR: 0.65, 95% CI: 0.51–0.84). Subgroup analysis of type of
mental comorbidity revealed that patients with comorbid anxiety
were 42% less likely to receive pharmacological treatment for
insomnia than those without anxiety (OR: 0.58, 95% CI:
0.45–0.73). CONCLUSION: Mental comorbidities such as
episodic mood disorder, anxiety, and depression are prevalent in
patients with insomnia and affect receipt of pharmacological
therapy for insomnia. Health care professionals should consider
the impact of mental comorbidities while treating patients with
sleep difﬁculties.
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OBJECTIVES: The objective of this study is to quantify the
strength of preferences of older Americans for possible
Alzheimer’s disease (AD) treatment beneﬁts by estimating their
willingness to accept the risk of death or severe disability in
exchange for modifying the course of AD. Currently, AD has no
cure. A breakthrough in treatment that modiﬁes the underlying
AD disease process would be a major achievement with enor-
mous medical and social beneﬁts. Little is known concerning
older Americans’ perceptions about AD and their willingness to
accept risk to avoid AD. METHODS: American residents aged
60 years and older who have not been diagnosed with AD, and
are not taking prescription medicines to treat AD, memory prob-
lems or dementia completed an online survey questionnaire that
included a series of stated-choice trade-off tasks. Respondents
chose between pairs of hypothetical treatment alternatives, each
including different 7-year AD disease-progression proﬁles and
risks of serious adverse events that would result in death or
severe disability. We used mixed-logit methods to estimate the
maximum acceptable risk (MAR) of serious adverse events that
would result in death or severe disability. RESULTS: 2146
respondents completed the survey. Mean (SD) age was 70 (7.4).
In return for preventing AD from progressing beyond the mild
stage, the mean MAR (95% CI) was 46.8% (40.3%–54.3%);
that is older Americans were willing, on average, to accept an
increase in the risk of death or severe disability from stroke of
nearly 50% to avoid progression to the moderate and severe
stages of AD. CONCLUSION: Older Americans’ willingness to
accept signiﬁcant increases in the risk of death or disability in
exchange for treatments that modify the course of AD indicates
the value of such treatment beneﬁts.
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OBJECTIVES: To assess the cost-effectiveness of using a lido-
caine 5% medicated plaster (lidocaine plaster) in the treatment
of post-herpetic neuralgia (PHN) in place of gabapentin from the
perspective of the Scottish National Health Service. METHODS:
A Markov model was constructed in TreeAge to calculate the
costs and beneﬁts of gabapentin and lidocaine plaster when used
in primary care over a six-month time horizon in patients with
